Targeted sequencing identifies risk variants in 202 candidate genes for neurodevelopmental disorders

• Published in: Gene 2024-03, Vol.897, p.148071-148071, Article 148071
• Main Authors: Pang, Nan, Li, Kuokuo, Tan, Senwei, Chen, Meilin, He, Fang, Chen, Chen, Yang, Lifen, Zhang, Ciliu, Deng, Xiaolu, Yang, Li, Mao, Leilei, Wang, Guoli, Duan, Haolin, Wang, Xiaole, Zhang, Wen, Guo, Hui, Peng, Jing, Yin, Fei, Xia, Kun
• Format: Article
• Language: English
• Subjects: autism; epilepsy; genes; genetic analysis; mutation; risk; sample size
• ISSN: 0378-1119; 1879-0038
• DOI: 10.1016/j.gene.2023.148071

With the continuous deepening of genetic research on neurodevelopmental disorders (NDDs), more patients have been identified the causal or candidate genes. However, it is still urgent needed to increase the sample size to confirm the associations between variants and clinical manifestations. We previously performed molecular inversion probe sequencing of autism spectrum disorder (ASD) candidate genes in 1,543 ASD patients. In this study, we used the same method to detect de novo variants (DNVs) in 665 NDD patients with intellectual disability (ID) and/or epilepsy (EP) for genetic analysis and diagnosis. We compared findings from ID/EP and ASD patients to improve our understanding of different subgroups of NDDs. We identified 72 novel variants and 39 DNVs. A totally of 5.71% (38/665) of the patients were genetically diagnosed by this sequencing strategy. ID/EP patients demonstrated a higher prevalence of likely gene disruptive DNVs in ASD genes than the healthy population. Regarding high-risk genes, SCN1A and CKDL5 were more frequently mutated in ID/EP patients than in ASD patients. Our data provide an overview of the mutation burden in ID/EP patients from the perspective of high risk ASD genes, indicating the differences and association of NDDs subgroups.